Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus ZADITOR.
PHENERGAN VC vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine